Real-world evidence shows Oncotype DX assists treatment decisions in hormone receptor-positive breast cancer, indicating potential for personalized therapy.
No takes yet. Share an insight, caveat, or question.
Oliveira et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: